Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Biological models and genes of tumor reversion: Cellular reprogramming through tpt1/TCTP and SIAH-1
Marcel Tuynder*,
Laurent Susini*,
Sylvie Prieur,
Stéphanie Besse,
Giusy Fiucci,
Robert Amson, and
Adam Telerman
Molecular Engines Laboratories, 20 Rue Bouvier, 75011 Paris, France
Accepted for publication September 6, 2002.
Received for publication June 19, 2002.
Abstract:
Tumor reversion is the process by which some cancer cells losetheir malignant phenotype. This study was aimed at definingsome of the molecular and phenotypic properties of this process.Biological models of tumor reversion were isolated from humanleukemia and breast cancer cell lines by using the H-1 parvovirusas a selective agent. Differential gene expression analysiswas performed between the parental malignant cells and theirrevertants or alternatively between these parental cells andtheir SIAH-1 transfectant counterparts. These SIAH-1 transfectantshave a suppressed malignant phenotype and were used as a controlfor a viral-free system. Two hundred sixty-three genes werefound to be either activated or inhibited during the reversionprocess, as confirmed by Northern blot analysis or quantitativePCR. Of these, 32% were differentially expressed in all systems,irrespective of whether parvovirus-selected, SIAH-1 overexpressing,or p53 mutant or wild-type cell lines were used, suggestingthe existence of a universal mechanism underlying tumor reversion.Translationally Controlled Tumor Protein (tpt1/TCTP) has thestrongest differential expression, down-regulated in the reversionof U937- and SIAH-1-overexpressing cells. Inhibition of TCTPexpression by anti-sense cDNA or small interfering RNA moleculesresults in suppression of the malignant phenotype and in cellularreorganization, similar to the effect of SIAH-1. Hence, tumorreversion can be defined at the molecular level, not just asthe reversal of malignant transformation, but as a biologicalprocess in its own right involving a cellular reprogrammingmechanism, overriding genetic changes in cancer, by triggeringan alternative pathway leading to suppression of tumorigenicity.
* M.T. and L.S. contributed equally to this work.
To whom correspondence should be addressed. E-mail: atelerman{at}molecular-engines.com.
Communicated by Georges Charpak, European Organization for NuclearResearch, Geneva, Switzerland
Data deposition: The sequences reported in this paper have beendeposited in the GenBank database (accession nos. BQ739779–BQ739784).
The editors suggest the following Related Resources on Science sites:
STEAP Proteins: From Structure to Applications in Cancer Therapy.
I. M. Gomes, C. J. Maia, and C. R. Santos (2012)
Mol. Cancer Res.
10, 573-587
|Abstract »|Full Text »|PDF »
A Novel TCTP Gene From the Crustacean Eriocheir sinensis: Possible Role Involving Metallic Cu2+ Stress.
Q. Wang, D.-A. Fang, W.-W. Li, J. Wang, and H. Jiang (2011)
Biol. Bull.
221, 290-299
|Abstract »|Full Text »|PDF »
Physical and Functional Antagonism between Tumor Suppressor Protein p53 and Fortilin, an Anti-apoptotic Protein.
Y. Chen, T. Fujita, D. Zhang, H. Doan, D. Pinkaew, Z. Liu, J. Wu, Y. Koide, A. Chiu, C. C.-J. Lin, et al. (2011)
J. Biol. Chem.
286, 32575-32585
|Abstract »|Full Text »|PDF »
Critical Roles of Translationally Controlled Tumor Protein in the Homeostasis and TCR-Mediated Proliferation of Peripheral T Cells.
P.-S. Wu, C.-Y. Yang, J. J.-Y. Yen, C.-H. Chou, S. H. Chen, C.-K. L. Wang, Y.-G. Lai, N.-S. Liao, and H.-F. Yang-Yen (2009)
J. Immunol.
183, 2373-2381
|Abstract »|Full Text »|PDF »
Complex relationship between TCTP, microtubules and actin microfilaments regulates cell shape in normal and cancer cells.
F. Bazile, A. Pascal, I. Arnal, C. Le Clainche, F. Chesnel, and J. Z. Kubiak (2009)
Carcinogenesis
30, 555-565
|Abstract »|Full Text »|PDF »
Characterization of TCTP, the Translationally Controlled Tumor Protein, from Arabidopsis thaliana.
O. Berkowitz, R. Jost, S. Pollmann, and J. Masle (2008)
PLANT CELL
20, 3430-3447
|Abstract »|Full Text »|PDF »
A Knockout Mouse Approach Reveals that TCTP Functions as an Essential Factor for Cell Proliferation and Survival in a Tissue- or Cell Type-specific Manner.
S. H. Chen, P.-S. Wu, C.-H. Chou, Y.-T. Yan, H. Liu, S.-Y. Weng, and H.-F. Yang-Yen (2007)
Mol. Biol. Cell
18, 2525-2532
|Abstract »|Full Text »|PDF »
Siah1 Interacts with the Scaffold Protein POSH to Promote JNK Activation and Apoptosis.
Z. Xu, A. Sproul, W. Wang, N. Kukekov, and L. A. Greene (2006)
J. Biol. Chem.
281, 303-312
|Abstract »|Full Text »|PDF »
The Translationally Controlled Tumor Protein Is a Novel Calcium Binding Protein of the Human Placenta and Regulates Calcium Handling in Trophoblast Cells.
F. Arcuri, S. Papa, A. Meini, A. Carducci, R. Romagnoli, L. Bianchi, M. G. Riparbelli, J.-C. Sanchez, M. Palmi, P. Tosi, et al. (2005)
Biol Reprod
73, 745-751
|Abstract »|Full Text »|PDF »
Stabilization and Enhancement of the Antiapoptotic Activity of Mcl-1 by TCTP.
H. Liu, H.-W. Peng, Y.-S. Cheng, H. S. Yuan, and H.-F. Yang-Yen (2005)
Mol. Cell. Biol.
25, 3117-3126
|Abstract »|Full Text »|PDF »
TSAP6 Facilitates the Secretion of Translationally Controlled Tumor Protein/Histamine-releasing Factor via a Nonclassical Pathway.
N. Amzallag, B. J. Passer, D. Allanic, E. Segura, C. Thery, B. Goud, R. Amson, and A. Telerman (2004)
J. Biol. Chem.
279, 46104-46112
|Abstract »|Full Text »|PDF »
Translationally controlled tumor protein is a target of tumor reversion.
M. Tuynder, G. Fiucci, S. Prieur, A. Lespagnol, A. Geant, S. Beaucourt, D. Duflaut, S. Besse, L. Susini, J. Cavarelli, et al. (2004)
PNAS
101, 15364-15369
|Abstract »|Full Text »|PDF »
Antiapoptotic Protein Partners Fortilin and MCL1 Independently Protect Cells from 5-Fluorouracil-induced Cytotoxicity.
P. Graidist, A. Phongdara, and K. Fujise (2004)
J. Biol. Chem.
279, 40868-40875
|Abstract »|Full Text »|PDF »
SIAH1 targets the alternative splicing factor T-STAR for degradation by the proteasome.
J. P. Venables, C. Dalgliesh, M. P. Paronetto, L. Skitt, J. K. Thornton, P. T. Saunders, C. Sette, K. T. Jones, and D. J. Elliott (2004)
Hum. Mol. Genet.
13, 1525-1534
|Abstract »|Full Text »|PDF »
Siah-1b is a direct transcriptional target of p53: Identification of the functional p53 responsive element in the siah-1b promoter.
G. Fiucci, S. Beaucourt, D. Duflaut, A. Lespagnol, P. Stumptner-Cuvelette, A. Geant, G. Buchwalter, M. Tuynder, L. Susini, J.-M. Lassalle, et al. (2004)
PNAS
101, 3510-3515
|Abstract »|Full Text »|PDF »
Translationally controlled tumor protein acts as a guanine nucleotide dissociation inhibitor on the translation elongation factor eEF1A.
C. Cans, B. J. Passer, V. Shalak, V. Nancy-Portebois, V. Crible, N. Amzallag, D. Allanic, R. Tufino, M. Argentini, D. Moras, et al. (2003)
PNAS
100, 13892-13897
|Abstract »|Full Text »|PDF »